MARKET

PRPH

PRPH

Prophase Labs Inc
NASDAQ
11.79
+0.13
+1.11%
Opening 15:51 10/04 EDT
OPEN
11.76
PREV CLOSE
11.66
HIGH
12.04
LOW
11.55
VOLUME
60.29K
TURNOVER
464.94K
52 WEEK HIGH
15.25
52 WEEK LOW
4.650
MARKET CAP
188.71M
P/E (TTM)
10.09
1D
5D
1M
3M
1Y
5Y
Are Medical Stocks Lagging ProPhase Labs (PRPH) This Year?
Here is how ProPhase Labs, Inc. (PRPH) and Concert Pharmaceuticals (CNCE) have performed compared to their sector so far this year.
Zacks · 09/08 13:40
ProPhase Labs to Present at the H.C. Wainwright 24th Annual Global Investment Conference September 12-14, 2022 (HYBRID CONFERENCE)
GARDEN CITY, NY, Sept. 06, 2022 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it will be featured as a presenting company at the H.C. Wainwright 24th Ann...
GlobeNewswire · 09/06 12:15
Here's Why ProPhase Labs, Inc. (PRPH) is a Great Momentum Stock to Buy
Does ProPhase Labs, Inc. (PRPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks · 08/25 16:00
Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?
Here is how DBV Technologies S.A. (DBVT) and ProPhase Labs, Inc. (PRPH) have performed compared to their sector so far this year.
Zacks · 08/23 13:40
BRIEF-ProPhase Labs Announces Record Second Quarter 2022 Financial Results
BRIEF-ProPhase Labs Announces Record Second Quarter 2022 Financial Results
Reuters · 08/11 13:57
ProPhase Labs, Inc. (PRPH) Tops Q2 Earnings and Revenue Estimates
ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of 233.33% and 28.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/11 13:25
ProPhase Labs GAAP EPS of $0.40 beats by $0.24, revenue of $29.09M beats by $5.77M
ProPhase Labs press release (NASDA...
Seekingalpha · 08/11 12:10
-- Earnings Flash (PRPH) PROPHASE LABS Posts Q2 Revenue $29.1M
-- Earnings Flash (PRPH) PROPHASE LABS Posts Q2 Revenue $29.1M
MT Newswires · 08/11 08:14
More
About PRPH
ProPhase Labs, Inc. is a diversified company that offers a range of services, including diagnostic testing, genomics testing and contract manufacturing. The Company operates through two segments: diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services. The Company is also engaged in the development and marketing of dietary supplements under the TK Supplements brand. The Company’s TK Supplements product line includes Legendz XL, a male sexual enhancement and Triple Edge XL, an energy and stamina booster.

Webull offers kinds of ProPhase Labs Inc stock information, including NASDAQ:PRPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PRPH stock methods without spending real money on the virtual paper trading platform.